About Us
Phagelux is a Canada platform company that utilizes phages and novel delivery systems to create first-in-class treatments for large unmet or under met skin conditions. Phagelux Targets are effectively preventing and treating AMR resistant topical infections. Phagelux has an R&D center in Montreal, Canada focused on bacteriophage products. Phagelux has significant IP and unique knowhow. In total, 11 patents have been filed in China, US, Europe, and other key markets, and 6 patents have been issued. These include patents of preparation method and method of use. In addition, Phagelux has unique platform knowhow in phage delivery. Phagelux has two products ready to start clinical trials.
We are focused on topical bacterial infection since the size of the market is so large and there are virtually no totally effective and affordable solutions. Over time, we will look to in-license other later stage biological dermatological treatments.
Mark Engel
CEO
Mr. Engel has been founding and building life sciences companies since 1990, including NPO Pharmaceuticals (successful exit); Excel PharmaStudies (successful exit); Tiger Medical Group (successful exit); and Haoyisheng (IPO ready). Mr. Engel also has a family fund investing in life science organizations.
Dr. Nancy Tawil
Chief Scientific Officer
Ph.Din Biomedical Engineering and Phage Expert
Sandy Li
Quality Manager
M.S.in Chemistry. Experienced in GMP
drug production
Bryan Li
EVP Medical
Dermatologist. China Medical University graduate, majored in Medicine, certified by American ECFMG, and specialized in Dermatology. Trained and worked at the Dermatology Departments of China Medical University and Guangdong Medical University. Dr. Li was a visiting scholar at the Dermatology Department of Asian University in South Korea and a post-doc research fellow at the Dermatology Department of Boston University, with several publications in peer-reviewed Journals. Mr. Li has nearly 30 years experience in medical and clinical operations at Fortune 500 multinationals.